en · de · es · fr · pt
selank-notes.peptides5388.com › Info › Selank Background And Peptide Chemistry — Beginner to Advanced

Selank Background And Peptide Chemistry — Beginner to Advanced

By Editorial Desk · published 2025-08-17 · last reviewed 2025-09-20 · Info

tuftsin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-09-20. Anything still debated is marked as such rather than presented as settled.

Selank Background and Peptide Chemistry

Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.

Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.

Background and Peptide Identity

Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.

Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.

Selank at a glance

PropertyValueNotes
Molecular formulaC33H57N11O9Derived from the seven-residue sequence
Molecular weightAbout 751.9 g/molAverage mass; the monoisotopic value is slightly lower
Residue countSeven amino acidsThr-Lys-Pro-Arg-Pro-Gly-Pro
Parent compoundTuftsin (Thr-Lys-Pro-Arg)Selank extends tuftsin at the C-terminus
Compound classSynthetic short peptideStudied in a research setting; not a licensed drug in most markets

Proposed Mechanisms and Research Endpoints

Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.

Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.

Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.

Related pages on this site

Background and Molecular Identity

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.

Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.

Identity and Structural Background

Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.

Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.

Further detail

where ST, TT denote the salinity and temperature at top layer, SB, TB denote the salinity and temperature at bottom layer, Ra is the Rayleigh Number, and Pr is the Prandtl Number. The sign of RaS and RaT will change depending on whether it stabilizes or destabilizes the system.

Single malt Scotch whisky must have been distilled at a single distillery as a batch process using a pot still distillation process and made from a mash of 100% malted barley. Single malt means that the whisky has not been blended elsewhere with whisky from other distilleries. A single malt Scotch must be distilled in Scotland and matured in oak casks in Scotland for at least three years, although most single malts are matured longer and also must be bottled in Scotland. Single grain Scotch whisky is a Scotch whisky distilled at a single distillery but, in addition to water and malted barley, may involve whole grains of other malted or unmalted cereals. Grain whisky can be distilled continuously in continuous stills or column stills. Single grain whisky can essentially be seen as any spirit from one distillery which qualifies as whisky but does not qualify as malt whisky. "Single grain" does not mean that only a single type of grain was used to produce the whisky; rather, the adjective "single" refers only to the use of a single distillery (and making a "single grain" generally requires using a mixture of grains, as barley is a type of grain and some malted barley must be used in all Scotch whisky - although a single grain whisky can be made entirely from malted barley and continuously distilled). Excluded from the definition of "single malt Scotch whisky" or "single grain Scotch whisky" is any spirit that qualifies as a blended Scotch whisky.

Lorcaserin, marketed under the brand name Belviq, was a weight-loss drug developed by Arena Pharmaceuticals. It reduces appetite by activating the 5-HT2C serotonin receptor in the hypothalamus, a region of the brain which is known to control appetite. It was approved in 2012, and in 2020 was removed from the market in the United States due to an increased risk of cancer detected in users of Belviq.

Sources: en.wikipedia.org

Background from the literature

=== HIV/AIDS-associated diarrhea === In a randomized controlled trial involving patients with advanced HIV/AIDS, S. boulardii supplementation was associated with a higher recovery rate from chronic diarrhea compared with placebo. Participants receiving S. boulardii also experienced weight gain, whereas those in the placebo group lost weight over the 18-month study period. No adverse reactions were reported in this immunocompromised population

The reason for using one or more housekeeping genes is to correct non-specific variation, such as the differences in the quantity and quality of RNA used, which can affect the efficiency of reverse transcription and therefore that of the whole PCR process. However, the most crucial aspect of the process is that the reference gene must be stable. The selection of these reference genes was traditionally carried out in molecular biology using qualitative or semi-quantitative studies such as the visual examination of RNA gels, northern blot densitometry or semi-quantitative PCR (PCR mimics). Now, in the genome era, it is possible to carry out a more detailed estimate for many organisms using transcriptomic technologies. However, research has shown that amplification of the majority of reference genes used in quantifying the expression of mRNA varies according to experimental conditions. It is therefore necessary to carry out an initial statistically sound methodological study in order to select the most suitable reference gene. A number of statistical algorithms have been developed that can detect which gene or genes are most suitable for use under given conditions. Those like geNORM or BestKeeper can compare pairs or geometric means for a matrix of different reference genes and tissues. The entire qPCR analysis workflow with proper error propagations is implemented in GenEx.

For services to the WRVS in Llanelh, Dyfed. Teresa Doonan. For services to the Glazert Activity Group, Lennox Castle Hospital, Glasgow. Marina Duckmanton, Management Pay Band 4, the Employment Service, Department for Education and Employment. James Duncan. For services to the Scout Association in Scotland. Denis Durno, , General Medical Practitioner, Portlethen, Aberdeenshire. For services to Medicine. Eric Anthony Dyer, Welfare Officer, National Grid Company plc. For services to Personnel Management. Elizabeth Stella Dyke. For services to the community in Sherborne, Dorset. Pamela Elaine Earl, Higher Executive Officer, Crown Prosecution Service. Mary Jean Easter, Clerical Assistant, Wiltshire Constabulary. For services to the Police. Daphne Viola Edginton. For services to the community in Milton-under-Wychwood, Oxfordshire. Geoffrey Stephen Edwards, Managing Director, Oxley Developments Company Ltd. For services to Industry. Harry Allen Edwards. For services to the Anglers Conservation Association. Michael Edwards, Administrative Officer, Department for Education and Employment. Pauline Edwards, Divisional Commandant, Special Constabulary, Dorset Police. For services to the Police. Margaret M. Eglington, lately Conductor, Billingham String Orchestra and Billingham Friday Choir, Cleveland Peripatetic Music Service. For services to Music Education. James Murray Elliot, lately Chairman, Scout Association, East Sussex. For services to Scouting. Brian Henry Ellis, Founder, Vision Aid Overseas. For Charitable Services. Pauline Ann Ellis. For services to the community in Derby.

Sources: en.wikipedia.org

Further detail

== Units of measurement == As some carotenoids can be converted into vitamin A, attempts have been made to determine how much of them in the diet is equivalent to a particular amount of retinol, so that comparisons can be made of the benefit of different foods. The situation can be confusing because the accepted equivalences have changed over time. For many years, a system of equivalencies in which an international unit (IU) was equal to 0.3 μg of retinol (~1 nmol), 0.6 μg of β-carotene, or 1.2 μg of other provitamin-A carotenoids was used. This relationship was alternatively expressed by the retinol equivalent (RE): one RE corresponded to 1 μg retinol, to 2 μg β-carotene dissolved in oil, to 6 μg β-carotene in foods, and to 12 μg of either α-carotene, γ-carotene, or β-cryptoxanthin in food. Newer research has shown that the absorption of provitamin-A carotenoids is only half as much as previously thought. As a result, in 2001 the US Institute of Medicine recommended a new unit, the retinol activity equivalent (RAE). Each μg RAE corresponds to 1 μg retinol, 2 μg of β-carotene in oil, 12 μg of "dietary" β-carotene, or 24 μg of the three other dietary provitamin-A carotenoids.

Austria signed the Treaty of Pressburg (26 December 1805) and left the coalition. The treaty required the Austrians to give up Venetia to the French-dominated Kingdom of Italy and the Tyrol to Bavaria. With the withdrawal of Austria from the war, stalemate ensued. Napoleon's army had a record of continuous unbroken victories on land, but the full force of the Russian army had not yet come into play. Napoleon had now consolidated his hold on France, had taken control of Belgium, the Netherlands, Switzerland, and most of Western Germany and northern Italy. His admirers say that Napoleon wanted to stop now, but was forced to continue in order to gain greater security from the countries that refused to accept his conquests. Esdaile rejects that explanation and instead says that it was a good time to stop expansion, for the major powers were ready to accept Napoleon as he was:

== Ureas == Urea (O=C(NH2)2) is more basic at oxygen than simple amides owing to the combined pi-donation from the two amino groups. One consequence is that the inventory of urea complexes is large, including many homoleptic derivatives. Urea forms a broader range of complexes, reflected by the existence of [M(urea)6](ClO4)3 (M = Ti, Mn). As for other complexes of carboxamide ligands, the MOC(NH2)2 core of urea is planar with a bent M-O-C angle. Biuret (H2NC(O)N(H)C(O)NH2) is a derivative of urea but with two amido groups. Biuret forms a variety of metal complexes, e.g. [Cu(H2NC(O)NHC(O)NH2)2]2+. In addition to the parent urea and biuret, many derivatives are known where N-H is replaced by alkyl or aryl.

Sources: en.wikipedia.org

Frequently asked questions

What is selank?

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.

How does selank differ from tuftsin?

Tuftsin contains four residues, while selank carries an additional Pro-Gly-Pro segment at the carboxyl end. That extension is intended to reduce enzymatic cleavage. Comparative pharmacokinetic data in humans remain limited.

Is the mechanism of action established?

No single receptor target is widely accepted as the definitive mediator of the reported effects. Proposed contributors include GABAergic modulation, shifts in monoamine turnover, and altered neuropeptide degradation. The mechanism is treated in the literature as unresolved.

What type of molecule is Selank?

Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.

Network